+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Urticaria- Pipeline Insight, 2025 - Product Thumbnail Image

Urticaria- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Mucopolysaccharidosis - Pipeline Insight, 2025 - Product Thumbnail Image

Mucopolysaccharidosis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Post-transplant Lymphoproliferative Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Ocular Graft Versus Host Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Ocular Graft Versus Host Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-33 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-33 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
CXCR4 Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

CXCR4 Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Chemokine Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Chemokine Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Androgenetic Alopecia - Pipeline Insight, 2025 - Product Thumbnail Image

Androgenetic Alopecia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Idiopathic Urticaria- Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Idiopathic Urticaria- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Insight, 2025 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Sanfilippo Syndrome Type A (MPS IIIA) - Pipeline Insight, 2025 - Product Thumbnail Image

Sanfilippo Syndrome Type A (MPS IIIA) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025 - Product Thumbnail Image

Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 75 Pages
  • Global
From
Juvenile Idiopathic Arthritis (JIA) - Pipeline Insight, 2025 - Product Thumbnail Image

Juvenile Idiopathic Arthritis (JIA) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Nasal Polyps - Pipeline Insight, 2025 - Product Thumbnail Image

Nasal Polyps - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Angioedema- Pipeline Insight, 2025 - Product Thumbnail Image

Angioedema- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Antibody-Mediated Graft Rejection - Pipeline Insight, 2025 - Product Thumbnail Image

Antibody-Mediated Graft Rejection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more